Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.

Kei MorioMichio ImamuraYoshiiku KawakamiYuki NakamuraMasahiro HatookaReona MorioHatsue FujinoTakashi NakaharaEisuke MurakamiTomokazu KawaokaMasataka TsugeAkira HiramatsuHiroshi AikataC Nelson HayesDaiki MikiHidenori OchiYoshio KatamuraKeiko AratakiTakashi MoriyaHiroyuki ItoKeiji TsujiHiroshi KohnoKoji WakiToru TamuraToshio NakamuraKazuaki Chayamanull null

Published in: Journal of medical virology (2018)

Both older and younger patients respond similarly to DAA therapy. Advanced liver fibrosis affects the virological response to sofosbuvir-based therapy.

Keyphrases

liver fibrosis
hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
physical activity
stem cells
hepatitis c virus infection
hiv infected
antiretroviral therapy
bone marrow
cell therapy
middle aged
community dwelling